Biohaven Pharmaceutical
Presença
Portage Biotech é uma empresa listada sob o símbolo PRTG (CA).
Portage Biotech tem presença direta em 3 países.Portage Biotech possui 3 subsidiárias incluindo Biohaven Pharmaceutical, BioShin e Sentien Biotech.
Eles estão dentro:
- Biotecnologia75%
- Farmacêutica25%
Fusão, aquisição e financiamento envolvendo Portage Biotech.
- Pfizer has announced the acquisition of Biohaven Pharmaceutical (publicado em 12 de maio de 2022).
Executivos
Veja o organograma con seus 121 executivos principais
Biografias mais buscadas da Biohaven Pharmaceutical
- Vlad Coric, Chief Executive Officer and Chairman of the Board
- Bob Hugin, Director
- John Childs, Director
Criar um alerta
para seguir os movimentos de executivos da Biohaven Pharmaceutical.
Farmacêutica
Portage Biotech possui 1.861 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Biohaven Pharmaceutical
- Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
- Biohaven Announces Record Date for Anticipated Spin-Off
- Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
- Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
- American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
- Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
- Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
- Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray
- Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society
- Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
- View more press releases Close
Redes sociais sobre Biohaven Pharmaceutical
- Biohaven Pharmaceutical na Wikipedia, Google News e Yahoo Finance
- Biohaven Pharmaceutical na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Vlad Coric 
Ligue para a Biohaven Pharmaceutical em +1 203...
